您的位置: 首页 > 2025年10月 第56卷 第10期 > 文字全文
2023年7月 第38卷 第7期11
目录

Th17/Treg与2型糖尿病患者胰岛素抵抗及胰岛β细胞功能的关系

Relationship among Th17/Treg,insulin resistance and islet β cell function in type 2 diabetic patients

来源期刊: 广州医药 | 1372-1377 发布时间:2025-10-20 收稿时间:2025/12/1 11:14:31 阅读量:122
作者:
关键词:
2型糖尿病 辅助性T17细胞 调节性T细胞 胰岛素抵抗
type 2 diabetes mellitus Th17 Treg insulin resistance
DOI:
10. 20223 / j. cnki. 1000-8535. 2025. 10. 007
收稿时间:
2024-08-06 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 观察辅助性T17细胞(Th17)与调节性T细胞(Treg)比值与2型糖尿病(T2DM)患者胰岛素抵抗及胰岛β细胞功能的关系。方法 纳入2022年4月—2023年4月在贵州医科大学第二附属医院内分泌科住院及健康体检人群各100例, 分为糖耐量正常组(NGT组, n=100)和T2DM组(n=100), 分别测定糖化血红蛋白(HbA1c)、空腹血糖(FPG)、甘油三酯(TG)等生化指标, 电化学发光法测定空腹胰岛素(FINS), 稳态模型计算胰岛β细胞功能指数(HOMA-β)、胰岛素抵抗指数(HOMA-IR)及胰岛素敏感指数(HOMA-ISI)。流式细胞术检测Th17、Treg水平。HOMA-IR、HOMA-β和HOMA-ISI的影响因素采用多元线性回归分析。结果 与NGT组相比, T2DM组BMI、FPG、HbA1c、LDL-C 、TG、TC、FINS、HOMA-IR、Th17及Th17/Treg水平均升高(P<0.01), HDL-C、HOMA-β、HOMA-ISI、Treg水平均降低, 且差异有统计学意义(P<0.01)。Th17与BMI(r=0.251, P<0.001)及HOMA-IR(r=0.305, P<0.001)呈正相关; 与HOMA-β(r=-0.204, P<0.001)及HOMA-ISI(r=-0.359, P<0.001)呈负相关。Treg与HOMA-ISI之间呈正相关(r=0.170, P=0.008), 而与HOMA-IR呈负相关(r=-0.153, P=0.017); Th17/Treg与BMI(r=0.332, P<0.001)及HOMA-IR(r=0.374, P<0.001);与HOMA-β(r=-0.249, P<0.001)及HOMA-ISI(r=-0.427, P<0.001)呈负相关。多元线性回归分析显示, Th17/Treg是HOMA-IR(β=5.915)升高及HOMA-ISI(β=-2.557)下降的影响因素(P<0.01)。结论 Th17/Treg可能通过影响胰岛素抵抗、降低胰岛素敏感性参与T2DM的发生。
Objective To explore the relationship among the proportion of helper T17 cells(Th17)to regulatory T cells(Treg), insulin resistance, and the function of islet beta cells.Methods One hundred cases of hospitalized patients and 100 cases of health check-ups people in the Department of Endocrinology of the Second Affiliated Hospital of Guizhou Medical University from April 2022 to April 2023 were included.Patients were divided into normal glucose tolerance group(NGT group, n=100)and type 2 diabetes mellitus group(T2DM group, n=100).The biochemical indexes of HbA1c, fasting blood glucose(FPG), triglyceride(TG)and fasting insulin(FINS)were determined by electrochemiluminescence.Islet beta cell function index(HOMA-β), insulin resistance index(HOMA-IR)and insulin sensitivity index(HOMA-ISI)were calculated in homeostasis model.The levels of Th17 and Treg were detected by flow cytometry.Spearman was used to analyze the correlation between indicators, and multiple linear regression analysis was used to analyze the influencing factors of HOMA-IR, HOMA-β and HOMA-ISI.Results In contrast to the NGT group, the T2DM group exhibited elevated levels of BMI, FPG, HbA1c, LDL-C, TG, TC, FINS, HOMA-IR, Th17 and Th17/Treg, with these variances being signifincantly different(P<0.01).There was a notable reduction in the levels of HDL-C,HOMA-β,HOMA-ISI,Treg,with those changes being significantly different(P<0.01).Th17 was positively correlated with BMI(r=0.251, P<0.001)and HOMA-IR(r=0.305, P<0.001), it was negatively correlated with HOMA-β(r=-0.204, P<0.001)and HOMA-ISI(r=-0.359, P<0.001).Treg was positively correlated with HOMA-ISI(r=0.170, P=0.008), while it was negatively correlated with HOMA-IR(r=-0.153, P=0.017).The ratio of Th17/Treg was positively correlated with BMI(r=0.332, P<0.001)and HOMA-IR(r=0.374, P<0.001), it was negatively correlated with HOMA-β(r=-0.249, P<0.001)and HOMA-ISI(r=-0.427, P<0.001).Multiple linear regression analysis showed that Th17/Treg was an influential factor in the increase of HOMA-IR(β=5.915)and the decrease of HOMA-ISI(β=-2.557)(P<0.01).Conclusions Th17/Treg may be involved in the development of T2DM by affecting insulin resistance and reducing insulin sensitivity.
       2型糖尿病(type 2 diabetes mellitus,T2DM)是一种全身代谢障碍性疾病,主要以血糖水平的提升为显著特点,其核心病因主要是由于胰岛素抵抗和胰岛β细胞功能的减退。我国的T2DM患者数量已经超越了1亿,其发病率也高于全球的平均水平[1]。T2DM及其并发症的高死亡率、高残疾率,降低患者生活质量,造成巨大经济压力[2-3]T2DM患者出现胰岛素抵抗和胰岛β细胞功能减退的具体分子机制仍不清楚[4],需要大量的研究证实。T细胞免疫是整个细胞免疫过程的关键环节。辅助性T17细胞(T helper cell 17,Th17)和调节性T细胞(regulatory T cells,Treg)是CD4+ T淋巴细胞体系中的两个亚型,它们都起源于初始T细胞状态。Th17细胞可以通过产生IL-21等炎性因子促进炎症和免疫性疾病的发展;Treg细胞可以通过分泌TGF-β及其他免疫抑制因子来调控免疫细胞分化与增殖[5]。二者互相抑制,构成动态平衡,使人体处于稳定状态,二者比例失调时,就可能引起疾病[6]。研究发现,Th17/Treg比值失衡与糖代谢异常有关[7]。目前关于Th17/Treg水平在T2DM患者中研究相对较少,本研究拟探讨Th17/Treg水平与T2DM患者胰岛素抵抗以及胰岛β细胞功能的关系,旨在揭示T2DM可能的发生机制,为T2DM的防治寻找新的思路。

1  资料与方法

1.1  研究对象及分组

        本研究为病例对照研究,纳入2022年4月—2023年4月在贵州医科大学第二附属医院内分泌科住院及健康体检人群各100例(预实验显示:T2DM患者中Th17/Treg比值的预期发生率为40%,健康对照组预计发生率为10%,显著性水平为0.05,统计把握度为80%,计算样本量为40例每组,查询Th17/Treg与T2DM的相关研究得知健康对照组和T2DM组的研究对象在30~80例之间)。根据OGTT试验分为糖耐量正常组(NGT组,n=100)和2型糖尿病组(T2DM组,n=100)。排除标准:1型糖尿病与特殊类型的糖尿病患者,患有严重的心血管、肾脏以及自身免疫性疾病,急慢性炎症等内分泌疾病、既往恶性肿瘤史、由其他疾病或药物引发的T2DM患者等。本研究经贵州医科大学第二附属医院伦理委员会批准(批件号:2023-伦审-229)。

1.2  资料采集

        收集记录性别、年龄、腰围、臀围、收缩压(systolic blood pressure,SBP)、舒张压(diastolic blood pressure,DBP)、身高、体质量等基线资料,计算体质指数(body mass index,BMI)=身高/体质2 (kg/m2 )、腰臀比(waist-to-hip ratio,WHR)=腰围/臀围。采集研究对象3 mL空腹血,利用全自动生化分析仪(Modular DPP-H7600)检测空腹血糖(fasting blood glucose,FPG)、甘油三酯(triglyceride,TG)、总胆固醇(total cholesterol,TC)、高密度脂蛋白胆固醇(high-density lipoprotein cholesterol,HDL-C)、低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C )等指标,高效液相色谱法( high performance liquid chromatography,HPLC,仪器型号:Bio-Rad D10)测糖化血红蛋白(HbA1c),电化学发光法测定空腹胰岛素(fasting insulin,FINS )。胰岛素抵抗指数( H O M A  I R )=FINS×FPG/22.5;HOMA-IR≤2.5为正常范围,>2.5为胰岛素抵抗;胰岛β细胞功能指数(HOMA β)=20×FINS/(FPG-3.5)≥100%为正常,<100%为胰岛β细胞功能受损;胰岛素敏感指数(HOMAISI)=1/FPG×FINS≥0.33为正常,<0.33为胰岛素敏感性降低。流式细胞术则用于检测受试者外周血单核细胞中的辅助性T17细胞(T helper cell 17,Th17)和调节性T细胞(regulatory T cells,Treg)水平,计算Th17/Treg比值。

1.3  统计学方法

       SPSS 22.0数据处理,符合正态分布的计量资料以表示,组间比较采用t检验,非正态分布资料以M(P25,P75)表示,组间比较采用Z检验,Person或Spearman法进行指标间相关性分析,多元线性回归分析HOMA-IR等的影响因素,P<0.05表示有统计学意义。

2  结 果

2.1  组间一般资料及生化指标比较

       与NGT组相比,T2DM组BMI、FPG、HbA1c、LDL-C、T G、T C等升高,HDL-C降低( P<0.001),见表1。

20251202162055_6930_thumb.png

2.2  组间胰岛素抵抗及胰岛β细胞功能比较

       与NGT组相比,T2DM组FINS、HOMA-IR升高,HOMA-β、HOMA-ISI降低(P<0.001),见表2。

20251202162118_2700_thumb.png

2.3  组间Th17、 Treg及Th17/ Treg比较

       与NGT组相比,T2DM组Th17及Th17/ Treg升高,Treg降低(P<0.001),见表3。
20251202162144_6917_thumb.png

2.4  Th17、Treg及Th17/ Treg与胰岛素抵抗、胰岛β细胞功能的相关性分析

        Th17与BMI(r=0.251,P<0.001)及HOMA-IR(r=0.305,P<0.001)呈正相关;与HOMA-βr=-0.204,P<0.001)及HOMA-ISI(r=-0.359,P<0.001)呈负相关。Treg与HOMA-ISI之间呈正相关(r=0.170,P=0.008),而与HOMA-IR呈负相关(r=-0.153,P=0.017);Th17/Treg与BMIr=0.332,P<0.001)及HOMA-IR(r=0.374,P<0.001);与HOMA-β(r=-0.249,P<0.001)及HOMA-ISI(r=-0.427,P<0.001)为负相关,见表4。

20251202162411_8500_thumb.png

2.5  影响胰岛素抵抗及胰岛β细胞功能的多元线性回归分析

        分别以HOMA-IR、HOMA-β及HOMA-ISI作为因变量Y1、Y2及Y3,年龄、WHR、TC、TG、LDL-C、HDL-C及Th17/Treg等分别作为自变量,进行多元线性回归分析,结果显示,HOMA-IR的多元线性回归方程为Y1=-1.410+0.510  TC+0.616LDL-C+5.915 Th17/Treg;HOMA-β的多元线性回归方程为Y2=5.763-0.015年龄+0.214LDL-C+0.648HDL-C;HOMA-ISI的多元线性回归方程为Y3=-2.420-0.199TC-0.360LDL-C-2.557Th17/Treg;综上,Th17/Treg是HOMA-IR升高及HOMA-ISI下降的影响因素(P<0.001),见表5。

表5   影响胰岛素抵抗及胰岛β细胞功能的多元线性回归分析

因变量

自变量

β

SE

t

P

95%CI

HOMA-IR

截距

-1.410

2.104

-0.670

0.504

-5.555~2.736

 

TC

0.510

0.162

3.147

0.002

0.191~0.829

 

LDL-C

0.616

0.183

3.374

0.001

0.256~0.976

 

Th17/Treg

5.915

1.211

4.883

<0.001 

3.528~8.302

HOMA-β

截距

5.763

0.965

5.975

<0.001 

3.863~7.664

 

年龄

-0.015

0.005

-2.974

0.003

-0.026~-0.005

 

LDL-C

0.214

0.084

2.551

0.011

0.049~0.379

 

HDL-C

0.648

0.195

3.324

0.001

0.264~1.032

HOMA-ISI

截距

-2.420 

0.818

-2.960

0.003

-4.031,-0.809

 

TC

-0.199

0.063

-3.163

0.002

-0.323~-0.075

 

LDL-C

-0.360

0.071

-5.074

<0.001 

-0.500~-0.220

 

Th17/Treg

-2.557

0.471

-5.432

<0.001 

-3.485~-1.630

 

3  讨 论

       T细胞在人体免疫系统中占据非常关键的位置,它在保持身体内免疫功能的均衡中发挥着至关重要的角色。如果出现T细胞异常,可能会引发疾病[6]。因此,寻找一种有效、安全的免疫抑制药物对于治疗因T细胞异常而引起的疾病至关重要。在国内外的众多研究中[8],有研究者指出Th17/Treg与糖尿病之间存在关联。Th17与Treg细胞分泌的IL-6等炎症因子,可能通过自身免疫反应损害胰岛β细胞,从而在T1DM的发病中发挥作用。然而,关于Th17/Treg在T2DM中的研究还相对较少,本文旨在探讨Th17/Treg与T2DM患者胰岛素抵抗及胰岛β细胞功能的关系。
       本研究显示T2DM组的FPG等糖代谢指标高于NGT组,这与Richter等[9]的研究发现相吻合,提示T2DM患者存在糖代谢异常。Dong等[10]对糖尿病与脂质代谢关系的研究发现,T2DM患者中的TC等指标高于NGT患者,表明T2DM患者同时合并异常的脂质代谢。通过检测受试者外周血Th17和Treg,结果显示,T2DM组的Th17和Th17/Treg高于NGT组,而Treg则相反,提示T2DM患者存在免疫系统失衡,这种Th17/Treg的失衡可能与T2DM的发病有关。有研究表明,Th17增加TNF-α等与炎症相关的因子释放,而TNF-α则能显著地抑制NF-κB激酶的活跃度,进而促使胰岛素受体底物的丝氨酸发生磷酸化,最终发生胰岛素抵抗[11]此外,Treg细胞具有分泌多种细胞因子以调控脂肪细胞表面转运载体-4表达的能力,这有助于减少胰岛素抵抗现象的出现。
       此外,本研究发现,与NGT组相比,T2DM组的HOMA-IR升高,而HOMA-β和HOMA-ISI下降,本研究结果与既往研究一致[12],这表明胰岛素的抵抗以及胰岛β细胞功能衰退是诱发糖尿病出现的核心因素。相关性分析发现,Th17/Treg与HOMA-IR呈正相关,与HOMA-β和HOMA-ISI呈现负相关。回归分析揭示,Th17/ Treg是HOMA-IR水平升高和HOMA-ISI下降的影响因素。表明Th17/Treg的失衡可能与T2DM患者胰岛素抵抗和胰岛β细胞功能减弱有关。Owusu等[13]认为,Th17/Treg失衡与T2DM患者的胰岛素抵抗和胰岛β细胞的功能损伤之间存在关联,与本研究结果一致。庄勤等[14]的研究,BMI与胰岛素抵抗以及T2DM的发生存在关联。本研究发现,T2DM组的BMI明显高于NGT组,Th17/Treg是促使BMI增高的关键因素,提示Th17/Treg失衡可能通过影响BMI参与T2DM的发生。一项研究指出,胰岛β细胞的分泌功能与血脂异常有密切的关联[14]。本研究发现,TC 升高是保护性因素,这与庄勤等 增加是HOMA-β降低的危险因素,但 [14]的研究结果 HDL-C相似。胰腺中轻度的脂质浸润或许与胰岛素的抵抗和早期分泌时间滞后相关,但严重的血脂浸润可能导致胰岛β细胞损伤以及胰岛素的分泌减少。近来有研究认为HDL-C升高可能有利于延缓T2DM患者胰岛β细胞功能下降,并减轻胰岛素抵[15]。在本研究中,T2DM组的HDL-C水平低于NGT组,提示HDL-C可能是导致HOMA-IR减少和HOMA-β增加的影响因素。刘晓妮等[16]对T2DM合并代谢综合征的患者进行分析,发现HDL-C与HOMA-IR之间存在负相关关系,本研究结果与之相似。
       本研究有以下不足之处,首先既往有研究发现,TGF-β/Smad3信号通路与T2DM的发生有关,而TGF-β可诱导Th17细胞因子的产生而起促炎介质的作用,从而影响葡萄糖代谢,Th17/Treg在TGF-β/Smad3通路中具体分子机制的研究有待进一步完善[17]。其次本研究为病例对照研究,且只选择了单个医疗机构人群为研究对象,未考虑地域、饮食习惯的影响,且未对研究对象进行随访,无法得知Th17/Treg的动态变化,具有一定局限性,这需要在今后的研究中加以验证。
       综上所述,Th17/Treg失衡可能通过影响胰岛素抵抗及降低胰岛β细胞功能参与T2DM的发生。以Th17/Treg为研究靶点,有利于揭示T2DM的发生机制及新药物的研发。


1、LIU%E2%80%83J%EF%BC%8CREN%E2%80%83Z%E2%80%83H%EF%BC%8CQIANG%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8ETrends%E2%80%83%20in%E2%80%83%0Athe%E2%80%83incidence%E2%80%83of%E2%80%83diabetes%E2%80%83mellitus%EF%BC%9AResults%E2%80%83from%E2%80%83the%E2%80%83%0AGlobal%E2%80%83Burden%E2%80%83of%E2%80%83Disease%E2%80%83Study%E2%80%832017%E2%80%83and%E2%80%83implications%E2%80%83%0Afor%E2%80%83diabetes%E2%80%83mellitus%E2%80%83prevention%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBMC%E2%80%83Public%E2%80%83%0AHealth%EF%BC%8C2020%EF%BC%8C20%EF%BC%881%EF%BC%89%EF%BC%9A1415%EF%BC%8ELIU%E2%80%83J%EF%BC%8CREN%E2%80%83Z%E2%80%83H%EF%BC%8CQIANG%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8ETrends%E2%80%83%20in%E2%80%83%0Athe%E2%80%83incidence%E2%80%83of%E2%80%83diabetes%E2%80%83mellitus%EF%BC%9AResults%E2%80%83from%E2%80%83the%E2%80%83%0AGlobal%E2%80%83Burden%E2%80%83of%E2%80%83Disease%E2%80%83Study%E2%80%832017%E2%80%83and%E2%80%83implications%E2%80%83%0Afor%E2%80%83diabetes%E2%80%83mellitus%E2%80%83prevention%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBMC%E2%80%83Public%E2%80%83%0AHealth%EF%BC%8C2020%EF%BC%8C20%EF%BC%881%EF%BC%89%EF%BC%9A1415%EF%BC%8E
2、RENNER%E2%80%83S%EF%BC%8CBLUTKE%E2%80%83A%EF%BC%8CCLAUSS%E2%80%83S%EF%BC%8Cet%E2%80%83al%EF%BC%8EPorcine%E2%80%83%0Amodels%E2%80%83for%E2%80%83studying%E2%80%83complications%E2%80%83and%E2%80%83organ%E2%80%83crosstalk%E2%80%83%0Ain%E2%80%83diabetes%E2%80%83mellitus%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECell%E2%80%83Tissue%E2%80%83Res%EF%BC%8C2020%EF%BC%8C%0A380%EF%BC%882%EF%BC%89%EF%BC%9A341-378%EF%BC%8ERENNER%E2%80%83S%EF%BC%8CBLUTKE%E2%80%83A%EF%BC%8CCLAUSS%E2%80%83S%EF%BC%8Cet%E2%80%83al%EF%BC%8EPorcine%E2%80%83%0Amodels%E2%80%83for%E2%80%83studying%E2%80%83complications%E2%80%83and%E2%80%83organ%E2%80%83crosstalk%E2%80%83%0Ain%E2%80%83diabetes%E2%80%83mellitus%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECell%E2%80%83Tissue%E2%80%83Res%EF%BC%8C2020%EF%BC%8C%0A380%EF%BC%882%EF%BC%89%EF%BC%9A341-378%EF%BC%8E
3、WILLIAMS%E2%80%83R%EF%BC%8CKARURANGA%E2%80%83S%EF%BC%8CMALANDA%E2%80%83B%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8EGlobal%E2%80%83and%E2%80%83%20regional%E2%80%83estimates%E2%80%83and%E2%80%83%20projections%E2%80%83%0Aof%E2%80%83diabetes-related%E2%80%83health%E2%80%83expenditure%EF%BC%9AResults%E2%80%83from%E2%80%83%0Athe%E2%80%83International%E2%80%83Diabetes%E2%80%83Federation%E2%80%83Diabetes%E2%80%83Atlas%EF%BC%8C%0A9th%E2%80%83edition%EF%BC%BBJ%EF%BC%BD%EF%BC%8EDiabetes%E2%80%83Res%E2%80%83Clin%E2%80%83Pract%EF%BC%8C2020%0A%EF%BC%88162%EF%BC%89%EF%BC%9A108072%EF%BC%8EWILLIAMS%E2%80%83R%EF%BC%8CKARURANGA%E2%80%83S%EF%BC%8CMALANDA%E2%80%83B%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8EGlobal%E2%80%83and%E2%80%83%20regional%E2%80%83estimates%E2%80%83and%E2%80%83%20projections%E2%80%83%0Aof%E2%80%83diabetes-related%E2%80%83health%E2%80%83expenditure%EF%BC%9AResults%E2%80%83from%E2%80%83%0Athe%E2%80%83International%E2%80%83Diabetes%E2%80%83Federation%E2%80%83Diabetes%E2%80%83Atlas%EF%BC%8C%0A9th%E2%80%83edition%EF%BC%BBJ%EF%BC%BD%EF%BC%8EDiabetes%E2%80%83Res%E2%80%83Clin%E2%80%83Pract%EF%BC%8C2020%0A%EF%BC%88162%EF%BC%89%EF%BC%9A108072%EF%BC%8E
4、GALICIA-GARCIA%E2%80%83U%EF%BC%8CBENITO-VICENTE%E2%80%83A%EF%BC%8C%0AJEBARI%E2%80%83S%EF%BC%8Cet%E2%80%83al%EF%BC%8EPathophysiology%E2%80%83of%E2%80%83type%E2%80%832%E2%80%83diabetes%E2%80%83%0Amellitus%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83J%E2%80%83Mol%E2%80%83Sci%EF%BC%8C2020%EF%BC%8C21%EF%BC%8817%EF%BC%89%EF%BC%9A%0A6275%EF%BC%8EGALICIA-GARCIA%E2%80%83U%EF%BC%8CBENITO-VICENTE%E2%80%83A%EF%BC%8C%0AJEBARI%E2%80%83S%EF%BC%8Cet%E2%80%83al%EF%BC%8EPathophysiology%E2%80%83of%E2%80%83type%E2%80%832%E2%80%83diabetes%E2%80%83%0Amellitus%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83J%E2%80%83Mol%E2%80%83Sci%EF%BC%8C2020%EF%BC%8C21%EF%BC%8817%EF%BC%89%EF%BC%9A%0A6275%EF%BC%8E
5、PEDERSEN%E2%80%83B%E2%80%83K%EF%BC%8EAnti-inflammatory%E2%80%83%20effects%E2%80%83%20of%E2%80%83%0Aexercise%EF%BC%9ARole%E2%80%83in%E2%80%83diabetes%E2%80%83and%E2%80%83cardiovascular%E2%80%83disease%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EEur%E2%80%83J%E2%80%83Clin%E2%80%83Invest%EF%BC%8C2017%EF%BC%8C47%EF%BC%888%EF%BC%89%EF%BC%9A600-611%EF%BC%8EPEDERSEN%E2%80%83B%E2%80%83K%EF%BC%8EAnti-inflammatory%E2%80%83%20effects%E2%80%83%20of%E2%80%83%0Aexercise%EF%BC%9ARole%E2%80%83in%E2%80%83diabetes%E2%80%83and%E2%80%83cardiovascular%E2%80%83disease%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EEur%E2%80%83J%E2%80%83Clin%E2%80%83Invest%EF%BC%8C2017%EF%BC%8C47%EF%BC%888%EF%BC%89%EF%BC%9A600-611%EF%BC%8E
6、WANG%E2%80%83M%EF%BC%8CCHEN%E2%80%83F%EF%BC%8CWANG%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8ETh17%E2%80%83%20and%E2%80%83%0ATreg%E2%80%83lymphocytes%E2%80%83in%E2%80%83obesity%E2%80%83and%E2%80%83Type%E2%80%832%E2%80%83diabetic%E2%80%83patients%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EClin%E2%80%83Immunol%EF%BC%8C2018%EF%BC%88197%EF%BC%89%EF%BC%9A77-85%EF%BC%8EWANG%E2%80%83M%EF%BC%8CCHEN%E2%80%83F%EF%BC%8CWANG%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8ETh17%E2%80%83%20and%E2%80%83%0ATreg%E2%80%83lymphocytes%E2%80%83in%E2%80%83obesity%E2%80%83and%E2%80%83Type%E2%80%832%E2%80%83diabetic%E2%80%83patients%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EClin%E2%80%83Immunol%EF%BC%8C2018%EF%BC%88197%EF%BC%89%EF%BC%9A77-85%EF%BC%8E
7、GUZM%C3%81N-FLORES%E2%80%83J%E2%80%83M%EF%BC%8CRAM%C3%8DREZ-EMILIANO%E2%80%83J%EF%BC%8C%0AP%C3%89REZ-V%C3%81ZQUEZ%E2%80%83V%EF%BC%8Cet%E2%80%83al%EF%BC%8ETh17%E2%80%83%20and%E2%80%83%20regulatory%E2%80%83T%E2%80%83cells%E2%80%83in%E2%80%83patients%E2%80%83with%E2%80%83different%E2%80%83time%E2%80%83of%E2%80%83progression%E2%80%83of%E2%80%83%0Atype%E2%80%832%E2%80%83diabetes%E2%80%83mellitus%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECent%E2%80%83Eur%E2%80%83J%E2%80%83Immunol%EF%BC%8C%0A2020%EF%BC%8C45%EF%BC%881%EF%BC%89%EF%BC%9A29-36%EF%BC%8EGUZM%C3%81N-FLORES%E2%80%83J%E2%80%83M%EF%BC%8CRAM%C3%8DREZ-EMILIANO%E2%80%83J%EF%BC%8C%0AP%C3%89REZ-V%C3%81ZQUEZ%E2%80%83V%EF%BC%8Cet%E2%80%83al%EF%BC%8ETh17%E2%80%83%20and%E2%80%83%20regulatory%E2%80%83T%E2%80%83cells%E2%80%83in%E2%80%83patients%E2%80%83with%E2%80%83different%E2%80%83time%E2%80%83of%E2%80%83progression%E2%80%83of%E2%80%83%0Atype%E2%80%832%E2%80%83diabetes%E2%80%83mellitus%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECent%E2%80%83Eur%E2%80%83J%E2%80%83Immunol%EF%BC%8C%0A2020%EF%BC%8C45%EF%BC%881%EF%BC%89%EF%BC%9A29-36%EF%BC%8E
8、DUAN%E2%80%83W%EF%BC%8CDING%E2%80%83Y%EF%BC%8CYU%E2%80%83X%EF%BC%8Cet%E2%80%83al%EF%BC%8EMetformin%E2%80%83%0Amitigates%E2%80%83autoimmune%E2%80%83insulitis%E2%80%83by%E2%80%83inhibiting%E2%80%83Th1%E2%80%83and%E2%80%83%0ATh17%E2%80%83responses%E2%80%83while%E2%80%83promoting%E2%80%83Treg%E2%80%83production%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AAm%E2%80%83J%E2%80%83Transl%E2%80%83Res%EF%BC%8C2019%EF%BC%8C11%EF%BC%884%EF%BC%89%EF%BC%9A2393-2402%EF%BC%8EDUAN%E2%80%83W%EF%BC%8CDING%E2%80%83Y%EF%BC%8CYU%E2%80%83X%EF%BC%8Cet%E2%80%83al%EF%BC%8EMetformin%E2%80%83%0Amitigates%E2%80%83autoimmune%E2%80%83insulitis%E2%80%83by%E2%80%83inhibiting%E2%80%83Th1%E2%80%83and%E2%80%83%0ATh17%E2%80%83responses%E2%80%83while%E2%80%83promoting%E2%80%83Treg%E2%80%83production%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AAm%E2%80%83J%E2%80%83Transl%E2%80%83Res%EF%BC%8C2019%EF%BC%8C11%EF%BC%884%EF%BC%89%EF%BC%9A2393-2402%EF%BC%8E
9、RICHTER%E2%80%83B%EF%BC%8CHEMMINGSEN%E2%80%83B%EF%BC%8CMETZENDORF%E2%80%83M%E2%80%83I%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8EDevelopment%E2%80%83of%E2%80%83type%E2%80%832%E2%80%83diabetes%E2%80%83mellitus%E2%80%83in%E2%80%83people%E2%80%83%0Awith%E2%80%83intermediate%E2%80%83hyperglycaemia%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECochrane%E2%80%83%0ADatabase%E2%80%83Syst%E2%80%83Rev%EF%BC%8C2018%EF%BC%8C10%EF%BC%8810%EF%BC%89%EF%BC%9ACD012661%EF%BC%8ERICHTER%E2%80%83B%EF%BC%8CHEMMINGSEN%E2%80%83B%EF%BC%8CMETZENDORF%E2%80%83M%E2%80%83I%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8EDevelopment%E2%80%83of%E2%80%83type%E2%80%832%E2%80%83diabetes%E2%80%83mellitus%E2%80%83in%E2%80%83people%E2%80%83%0Awith%E2%80%83intermediate%E2%80%83hyperglycaemia%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECochrane%E2%80%83%0ADatabase%E2%80%83Syst%E2%80%83Rev%EF%BC%8C2018%EF%BC%8C10%EF%BC%8810%EF%BC%89%EF%BC%9ACD012661%EF%BC%8E
10、DONG%E2%80%83W%EF%BC%8CYAN%E2%80%83S%EF%BC%8CCHEN%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8EA%E2%80%83association%E2%80%83%0Aof%E2%80%83remnant%E2%80%83cholesterol%E2%80%83and%E2%80%83newly%E2%80%83diagnosed%E2%80%83early-onset%E2%80%83%0Atype%E2%80%832%E2%80%83diabetes%E2%80%83mellitus%E2%80%83in%E2%80%83Chinese%E2%80%83population%EF%BC%9AA%E2%80%83%0Aretrospective%E2%80%83cross-sectional%E2%80%83study%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Diabetes%EF%BC%8C%0A2024%EF%BC%8C16%EF%BC%882%EF%BC%89%EF%BC%9Ae13498%EF%BC%8EDONG%E2%80%83W%EF%BC%8CYAN%E2%80%83S%EF%BC%8CCHEN%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8EA%E2%80%83association%E2%80%83%0Aof%E2%80%83remnant%E2%80%83cholesterol%E2%80%83and%E2%80%83newly%E2%80%83diagnosed%E2%80%83early-onset%E2%80%83%0Atype%E2%80%832%E2%80%83diabetes%E2%80%83mellitus%E2%80%83in%E2%80%83Chinese%E2%80%83population%EF%BC%9AA%E2%80%83%0Aretrospective%E2%80%83cross-sectional%E2%80%83study%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Diabetes%EF%BC%8C%0A2024%EF%BC%8C16%EF%BC%882%EF%BC%89%EF%BC%9Ae13498%EF%BC%8E
11、杨凌辉,邹大进.肥胖致胰岛素抵抗的机制[J].中华内分泌代谢杂志,2002,18(3):244-246.杨凌辉,邹大进.肥胖致胰岛素抵抗的机制[J].中华内分泌代谢杂志,2002,18(3):244-246.
12、HUA%E2%80%83K%E2%80%83F%EF%BC%8CZHANG%E2%80%83M%E2%80%83Y%EF%BC%8CZHANG%E2%80%83Y%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0ACharacteristics%E2%80%83of%E2%80%83OGTT%E2%80%83and%E2%80%83correlation%E2%80%83%20between%E2%80%83the%E2%80%83%0Ainsulin%E2%80%83to%E2%80%83C-peptide%E2%80%83molar%E2%80%83ratio%EF%BC%8CHOMA-IR%EF%BC%8Cand%E2%80%83%0Ainsulin%E2%80%83antibodies%E2%80%83in%E2%80%83T2DM%E2%80%83patients%EF%BC%BBJ%EF%BC%BD%EF%BC%8EDiabetes%E2%80%83%0AMetab%E2%80%83Syndr%E2%80%83Obes%EF%BC%8C2022%EF%BC%8815%EF%BC%89%EF%BC%9A2417-2425%EF%BC%8EHUA%E2%80%83K%E2%80%83F%EF%BC%8CZHANG%E2%80%83M%E2%80%83Y%EF%BC%8CZHANG%E2%80%83Y%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0ACharacteristics%E2%80%83of%E2%80%83OGTT%E2%80%83and%E2%80%83correlation%E2%80%83%20between%E2%80%83the%E2%80%83%0Ainsulin%E2%80%83to%E2%80%83C-peptide%E2%80%83molar%E2%80%83ratio%EF%BC%8CHOMA-IR%EF%BC%8Cand%E2%80%83%0Ainsulin%E2%80%83antibodies%E2%80%83in%E2%80%83T2DM%E2%80%83patients%EF%BC%BBJ%EF%BC%BD%EF%BC%8EDiabetes%E2%80%83%0AMetab%E2%80%83Syndr%E2%80%83Obes%EF%BC%8C2022%EF%BC%8815%EF%BC%89%EF%BC%9A2417-2425%EF%BC%8E
13、%E2%80%83%20OWUSU%E2%80%83ADJAH%E2%80%83E%E2%80%83S%EF%BC%8CBELLARY%E2%80%83S%EF%BC%8CHANIF%E2%80%83W%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8EPrevalence%E2%80%83and%E2%80%83incidence%E2%80%83of%E2%80%83complications%E2%80%83at%E2%80%83%0Adiagnosis%E2%80%83of%E2%80%83T2DM%E2%80%83and%E2%80%83during%E2%80%83follow-up%E2%80%83by%E2%80%83BMI%E2%80%83and%E2%80%83%0Aethnicity%EF%BC%9AA%E2%80%83matched%E2%80%83case-control%E2%80%83analysis%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0ACardiovasc%E2%80%83Diabetol%EF%BC%8C2018%EF%BC%8C17%EF%BC%881%EF%BC%89%EF%BC%9A70%EF%BC%8E%E2%80%83%20OWUSU%E2%80%83ADJAH%E2%80%83E%E2%80%83S%EF%BC%8CBELLARY%E2%80%83S%EF%BC%8CHANIF%E2%80%83W%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8EPrevalence%E2%80%83and%E2%80%83incidence%E2%80%83of%E2%80%83complications%E2%80%83at%E2%80%83%0Adiagnosis%E2%80%83of%E2%80%83T2DM%E2%80%83and%E2%80%83during%E2%80%83follow-up%E2%80%83by%E2%80%83BMI%E2%80%83and%E2%80%83%0Aethnicity%EF%BC%9AA%E2%80%83matched%E2%80%83case-control%E2%80%83analysis%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0ACardiovasc%E2%80%83Diabetol%EF%BC%8C2018%EF%BC%8C17%EF%BC%881%EF%BC%89%EF%BC%9A70%EF%BC%8E
14、庄勤,赵舒然,李飞艳,等.糖尿病前期胰岛β细胞早期功能缺陷的影响因素研究[J].海南医学院学报,2020,26(14):1092-1097,1104.庄勤,赵舒然,李飞艳,等.糖尿病前期胰岛β细胞早期功能缺陷的影响因素研究[J].海南医学院学报,2020,26(14):1092-1097,1104.
15、%E2%80%83%20ZAKERKISH%E2%80%83M%EF%BC%8CJENABI%E2%80%83M%EF%BC%8CZAEEMZADEH%E2%80%83%0AN%EF%BC%8Cet%E2%80%83al%EF%BC%8EThe%E2%80%83effect%E2%80%83of%E2%80%83%20Iranian%E2%80%83%20propolis%E2%80%83on%E2%80%83glucose%E2%80%83%0Ametabolism%EF%BC%8Clipid%E2%80%83profile%EF%BC%8Cinsulin%E2%80%83resistance%EF%BC%8Crenal%E2%80%83%0Afunction%E2%80%83and%E2%80%83inflammatory%E2%80%83biomarkers%E2%80%83in%E2%80%83patients%E2%80%83with%E2%80%83%0Atype%E2%80%832%E2%80%83diabetes%E2%80%83mellitus%EF%BC%9AA%E2%80%83%20randomized%E2%80%83double-blind%E2%80%83%0Aclinical%E2%80%83trial%EF%BC%BBJ%EF%BC%BD%EF%BC%8ESci%E2%80%83Rep%EF%BC%8C2019%EF%BC%8C9%EF%BC%881%EF%BC%89%EF%BC%9A7289%EF%BC%8E%E2%80%83%20ZAKERKISH%E2%80%83M%EF%BC%8CJENABI%E2%80%83M%EF%BC%8CZAEEMZADEH%E2%80%83%0AN%EF%BC%8Cet%E2%80%83al%EF%BC%8EThe%E2%80%83effect%E2%80%83of%E2%80%83%20Iranian%E2%80%83%20propolis%E2%80%83on%E2%80%83glucose%E2%80%83%0Ametabolism%EF%BC%8Clipid%E2%80%83profile%EF%BC%8Cinsulin%E2%80%83resistance%EF%BC%8Crenal%E2%80%83%0Afunction%E2%80%83and%E2%80%83inflammatory%E2%80%83biomarkers%E2%80%83in%E2%80%83patients%E2%80%83with%E2%80%83%0Atype%E2%80%832%E2%80%83diabetes%E2%80%83mellitus%EF%BC%9AA%E2%80%83%20randomized%E2%80%83double-blind%E2%80%83%0Aclinical%E2%80%83trial%EF%BC%BBJ%EF%BC%BD%EF%BC%8ESci%E2%80%83Rep%EF%BC%8C2019%EF%BC%8C9%EF%BC%881%EF%BC%89%EF%BC%9A7289%EF%BC%8E
16、刘晓妮,王颖,李桃桃,等.2型糖尿病合并代谢综合征患者胰岛素抵抗指数与慢性炎症指标相关性研究[J].检验医学,2019,34(9):826-830.刘晓妮,王颖,李桃桃,等.2型糖尿病合并代谢综合征患者胰岛素抵抗指数与慢性炎症指标相关性研究[J].检验医学,2019,34(9):826-830.
17、LIN%E2%80%83H%E2%80%83M%EF%BC%8CLEE%E2%80%83J%E2%80%83H%EF%BC%8CYADAV%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8ETransforming%E2%80%83%0Agrowth%E2%80%83factor-beta%2FSmad3%E2%80%83%20signaling%E2%80%83%20regulates%E2%80%83insulin%E2%80%83%0Agene%E2%80%83transcription%E2%80%83%20and%E2%80%83%20pancreatic%E2%80%83islet%E2%80%83%20beta-cell%E2%80%83%0Afunction%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Biol%E2%80%83Chem%EF%BC%8C2009%EF%BC%8C284%EF%BC%8818%EF%BC%89%EF%BC%9A%0A12246-12257%EF%BC%8ELIN%E2%80%83H%E2%80%83M%EF%BC%8CLEE%E2%80%83J%E2%80%83H%EF%BC%8CYADAV%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8ETransforming%E2%80%83%0Agrowth%E2%80%83factor-beta%2FSmad3%E2%80%83%20signaling%E2%80%83%20regulates%E2%80%83insulin%E2%80%83%0Agene%E2%80%83transcription%E2%80%83%20and%E2%80%83%20pancreatic%E2%80%83islet%E2%80%83%20beta-cell%E2%80%83%0Afunction%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Biol%E2%80%83Chem%EF%BC%8C2009%EF%BC%8C284%EF%BC%8818%EF%BC%89%EF%BC%9A%0A12246-12257%EF%BC%8E
1、贵州省卫健委课题(gzwkj2024-314); 黔东南州科学技术局课题(黔东南科合J字【2023】94号)()
上一篇
下一篇
出版者信息








《广州医药》公众号
目录